Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12612001209886
Ethics application status
Approved
Date submitted
6/11/2012
Date registered
15/11/2012
Date last updated
6/08/2018
Type of registration
Retrospectively registered
Titles & IDs
Public title
Assessment of Fatty Acid/Carnitine Homeostasis in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)
Query!
Scientific title
Assessment of Fatty Acid/Carnitine Homeostasis in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)
Query!
Secondary ID [1]
281504
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
287774
0
Query!
Condition category
Condition code
Other
288122
288122
0
0
Query!
Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Observational study of fatty acid/carnitine homeostasis in CFS/ME. Participants will provide a single fasting blood sample from which plasma free fatty acid and carnitine levels will be determined and the ratio of fatty acid/carnitine levels calculated. In a sub-group of participants, assessment will also be conducted using standard 13C-oleic acid breath testing and baseline corrected expired air 13CO2 concentration-time data will be kinetically modelled to determine the rate and extent of fatty acid oxidation.
Query!
Intervention code [1]
286019
0
Not applicable
Query!
Comparator / control treatment
Assessment of fatty acid/carnitine homeostasis in a sub-group of healthy controls
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
288326
0
The primary objective of this study is to determine the ratio of free fatty acid/acylcarnitine for a wide range of fatty acids, as an index of fatty acid/carnitine homeostasis, in patients with CFS/ME compared to healthy controls, and the possible application of this information as a diagnostic criterion in CFS/ME.
Participants will provide a single fasting blood sample from which plasma free fatty acid and carnitine levels will be determined and the ratio of fatty acid/carnitine levels calculated. Ratios will be compared between the study populations using an analysis of variance (ANOVA) to determine if a difference exists.
Query!
Assessment method [1]
288326
0
Query!
Timepoint [1]
288326
0
Single-point assessment
Query!
Primary outcome [2]
288373
0
The relationship between the ratio of fatty acid/carnitine levels and quality-of-life (assessed via Medical Outcomes Study Short-Form 36 questionnaire) and fatigue severity (assessed via Fatigue Severity Scale) will be examined using linear regression.
Query!
Assessment method [2]
288373
0
Query!
Timepoint [2]
288373
0
Single-point assessment
Query!
Secondary outcome [1]
299859
0
The secondary objective of this study is to determine the rate and extent of fatty acid oxidation, as indicated by the 13C fatty acid breath test, in patients with CFS/ME compared to healthy controls, and to assess the suitability of this test for the clinical diagnosis of CFS/ME.
In a sub-group of participants, assessment will also be conducted using standard 13C-oleic acid breath testing and baseline corrected expired air 13CO2 concentration-time data will be kinetically modelled to determine the rate and extent of fatty acid oxidation. Breath test results will be compared between the study populations using an analysis of variance (ANOVA) to determine if a difference exists.
Query!
Assessment method [1]
299859
0
Query!
Timepoint [1]
299859
0
Single-point assessment
Query!
Secondary outcome [2]
299993
0
The relationship between breath test results and quality-of-life (assessed via Medical Outcomes Study Short-Form 36 questionnaire) and fatigue severity (assessed via Fatigue Severity Scale) will be examined using linear regression.
Query!
Assessment method [2]
299993
0
Query!
Timepoint [2]
299993
0
Single-point assessment
Query!
Eligibility
Key inclusion criteria
1. Participant is >=18 years of age at the time of informed consent.
2. Participant is a male or non-pregnant, non-lactating female.
3. Participant is either:
i. a patient diagnosed with CFS/ME by a physician according to the standard diagnostic criteria; or
ii. a healthy subject with no clinically significant conditions.
4. Participant is aware of the study procedures and the risks involved and voluntarily agrees to participate by providing written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Participant has received treatment with L-carnitine or any carnitine derivatives within 2 months of study participation.
2. Participant has received treatment with fatty acid-containing products within 2 months of study participation.
3. Participant has received treatment with a pharmacologic agent known to alter fatty acid/carnitine homeostasis within 2 months of study participation.
4. Participant has a known blood-borne viral infection, including HIV, Hepatitis B or Hepatitis C.
5. Participant has a history or current evidence of any condition, therapy or laboratory abnormality that, in the opinion of the investigator, might affect the results of the study or may not be in the best interest of the individual to participate.
6. Participant has participated in a clinical trial within 2 months of study participation that, in the opinion of the investigator, might affect the results of the study or may not be in the best interest of the individual to participate.
Query!
Study design
Purpose
Natural history
Query!
Duration
Cross-sectional
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
17/08/2012
Query!
Actual
5/09/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
1/08/2013
Query!
Date of last data collection
Anticipated
Query!
Actual
19/08/2013
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
88
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Funding & Sponsors
Funding source category [1]
286285
0
Charities/Societies/Foundations
Query!
Name [1]
286285
0
The Judith Jane Mason and Harold Stannett Williams Memorial Foundation
Query!
Address [1]
286285
0
ANZ Trustees
GPO Box 389
Melbourne, VIC, 3001
Query!
Country [1]
286285
0
Australia
Query!
Primary sponsor type
University
Query!
Name
University of South Australia
Query!
Address
CEA-19, GPO Box 2471
Adelaide, SA, 5001
Query!
Country
Australia
Query!
Secondary sponsor category [1]
285080
0
None
Query!
Name [1]
285080
0
Query!
Address [1]
285080
0
Query!
Country [1]
285080
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
288357
0
University of South Australia Human Research Ethics Committee
Query!
Ethics committee address [1]
288357
0
GPO Box 2471 Adelaide, SA, 5001
Query!
Ethics committee country [1]
288357
0
Australia
Query!
Date submitted for ethics approval [1]
288357
0
09/07/2012
Query!
Approval date [1]
288357
0
17/08/2012
Query!
Ethics approval number [1]
288357
0
0000030308
Query!
Summary
Brief summary
Single fasting blood samples will be collected from each study participant for analysis of endogenous plasma L carnitine, acylcarnitine and free fatty acid concentrations. Results will be utilised for the determination of indices of fatty acid/carnitine homeostasis, calculated as the ratio of plasma free fatty acid – acylcarnitine. At the time of blood sample collection, each study participant will complete validated questionnaires for assessment of fatigue severity (Fatigue Severity Scale) and quality of life (Medical Outcomes Study Short-Form 36, SF 36). 13C oleic acid breath testing will be conducted in a subgroup of participants. After an overnight fast, participants will be administered a single 50 mg oral dose of 13C oleic acid. Expired air samples will be collected prior to dose administration (baseline) and then at hourly intervals until 8 hours post-dose for analysis of 13CO2 content. Baseline-corrected expired air 13CO2 concentration-time data will be kinetically modelled to determine the rate and extent of oxidation of oleic acid. Results of fatty acid/carnitine profiling and 13C oleic acid breath testing obtained from patients with CFS/ME will be statistically compared to those obtained from healthy controls using analysis of variance (ANOVA). Statistical examination of the relationship between the determined indices of fatty acid oxidation and fatigue severity/quality of life will be conducted using linear regression.
Query!
Trial website
Query!
Trial related presentations / publications
None.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
34925
0
Dr Stephanie Reuter Lange
Query!
Address
34925
0
University of South Australia
CEA-19, GPO Box 2471
Adelaide SA 5001
Query!
Country
34925
0
Australia
Query!
Phone
34925
0
+61883021872
Query!
Fax
34925
0
Query!
Email
34925
0
[email protected]
Query!
Contact person for public queries
Name
18172
0
Stephanie Reuter Lange
Query!
Address
18172
0
CEA-19, GPO Box 2471
Adelaide, SA, 5001
Query!
Country
18172
0
Australia
Query!
Phone
18172
0
+61 8 8302 1872
Query!
Fax
18172
0
Query!
Email
18172
0
[email protected]
Query!
Contact person for scientific queries
Name
9100
0
Stephanie Reuter Lange
Query!
Address
9100
0
CEA-19, GPO Box 2471
Adelaide, SA, 5001
Query!
Country
9100
0
Australia
Query!
Phone
9100
0
+61 8 8302 1872
Query!
Fax
9100
0
Query!
Email
9100
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF